<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610463</url>
  </required_header>
  <id_info>
    <org_study_id>MEASURE-PFO</org_study_id>
    <nct_id>NCT04610463</nct_id>
  </id_info>
  <brief_title>Evaluation of the Severity of Right to Left Shunt in PFO Patients After Systemic Embolism</brief_title>
  <official_title>Evaluation of the Severity of Right to Left Shunt in Patent Foraneb Ovale Patients After Systemic Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Hradec Kralove</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Hradec Kralove</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the project is to identify new risk indicators of PFO. The evaluation of the R-L&#xD;
      shunt is based on the newly developed precise measurement technique. Moreover, this&#xD;
      measurement of R-L shunt is feasible in a case when R-L shunt is present only intermittently.&#xD;
      Multicentric study with 150 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the proposed project is to identify new risk indicators of PFO. The evaluation of&#xD;
      the R-L shunt is based on the newly developed precise measurement technique. Moreover, this&#xD;
      measurement of R-L shunt is feasible in a case when R-L shunt is present only intermittently.&#xD;
&#xD;
      Detection and quantification of R-L shunt will be realized by the original INNTHERM® ® system&#xD;
      (Innova Medical s.r.o., Velká Dobrá). This system is based on the principle of&#xD;
      thermodilution.&#xD;
&#xD;
      The basic assumption of our study is the hypothesis, that the size of the R-L shunt (and&#xD;
      especially its maximum size during intra-abdominal pressure increase) is a risk factor for&#xD;
      the development of paradoxical embolism (from pulmonary to systemic circulation). The most&#xD;
      critical consequence of paradoxical embolism is the development of ischemic stroke.&#xD;
&#xD;
      Such measurement with an unequivocal accuracy has never been done so far, due a lack of&#xD;
      technology precise enough.&#xD;
&#xD;
      Precise quantification of R-L shunt will allow a more accurate prediction of high-risk&#xD;
      patients, especially after correlation with commonly used methods. PFO is now an indication&#xD;
      for implantation of percutaneous occlusion device only in case of secondary prevention of&#xD;
      stroke, i.e. in a group of patients who have had an ischemic stroke.&#xD;
&#xD;
      Prospectively, precise and better identification of a risk group of these patients could lead&#xD;
      to cost reduction of treatment. This cost reduction is crucial for young working-age patients&#xD;
      who can be treated before a major irreversible brain injury occurs.&#xD;
&#xD;
      A parameter applicable in primary prevention saves the cost of ischemic stroke treatment and&#xD;
      other systemic embolism; additionally it will contribute to cost reduction during aftercare&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of R-L shunt namely</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Right-to Left shunt will be measured and quantified using by the novel system for measurement of Cardiac flow- Inntherm. We will obtain these hemodynamics parameters: Systemic blood flow (SBF) pulmonary blood (PBF) Cardiac index (CI), ration of QP/QS. Right to left shunt will be quantified in liters per minutes as well as % of SBF and % of PBF.&#xD;
We will evaluate R-L shunt in normal conditions as well as after inducible Valsalva maneuver.&#xD;
Each patient will fill EQ-5D at the beginning of the study and Then 24 weeks after PFO closure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transesophageal Echocardiography examination before Patent foramen ovale closure</measure>
    <time_frame>Up to 24 weeks (Prior subject's Patent foramen ovale closure)</time_frame>
    <description>To evaluate the morphology of atrial septum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the severity of Right-Left shunt and comparison with atrial septal morphology</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Is there a significant correlation between atrial septal morphology and the level of severity of cardiac shunt as a predictive factor for systemic embolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spiroergometric examination with the measurement of VO2max</measure>
    <time_frame>6 months after Patent foramen ovale closure by means of a Patent foramen ovale occluder</time_frame>
    <description>Detection of possible desaturation using the spiroergometric examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spiroergometric examination with the measurement of SpO2</measure>
    <time_frame>6 months after Patent foramen ovale closure by means of a Patent foramen ovale occluder</time_frame>
    <description>Detection of possible desaturation using the spiroergometric examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transesophageal Echocardiography routine examination after 6 months after Patent foramen ovale closure</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>To evaluate results 6 months after Patent foramen ovale closure by means of a Patent foramen ovale occluder with a routine examination of Transesophageal Echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of significant R-L shunt on exercise tolerance and quality of life of the patient</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>To judge if the closure of Patent foramen ovale especially by the group of patients with significant R-L shunt may influence exercise tolerance and quality of patient life. Precise results of quantification of R-L Shunt will significantly correlated with a possible complications of PFO - systemic embolization, desaturation syndromes.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Patent Foramen Ovale</condition>
  <condition>Embolism</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects indicated for patent foramen ovale closure to prevent a relapse of systemic embolism</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac flow measurement</intervention_name>
    <description>Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients aged ≥18 and &lt; 60 years&#xD;
&#xD;
          2. Cryptogenic stroke or Systemic embolization due to paradoxical embolization via Patent&#xD;
             Foramen Ovale&#xD;
&#xD;
          3. The patient indicated for occlusion of PFO with catheter occluder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to perform spiroergometry&#xD;
&#xD;
          2. Inability to perform Transesophageal echocardiography (TEE)&#xD;
&#xD;
          3. Inability to perform proper Valsalva maneuver&#xD;
&#xD;
          4. Inability to understand and/or signed informed consent form&#xD;
&#xD;
          5. Contraindication of Patent Foramen Ovale occlusion by any medical reason or patient&#xD;
             refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Josef Šťásek</last_name>
    <phone>+420495832248</phone>
    <email>josef.stasek@fnhk.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johana Krempová</last_name>
    <phone>+420601087319</phone>
    <email>johana.krempova@fnhk.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fakultní nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Poloczek</last_name>
      <phone>+420532232458</phone>
      <email>martin.poloczek@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Martin Poloczek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I. interní kardioangiologická klinika, Fakultní nemocnice Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Šťásek</last_name>
      <phone>+420495832248</phone>
      <email>josef.stasek@fnhk.cz</email>
    </contact>
    <investigator>
      <last_name>Josef Šťásek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marian Branny</last_name>
      <phone>+420 597 374 024</phone>
      <email>marian.branny@fno.cz</email>
    </contact>
    <investigator>
      <last_name>Marian Branny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Praga</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Mates</last_name>
      <phone>+420 257 272 213</phone>
      <email>martin.mates@homolka.cz</email>
    </contact>
    <investigator>
      <last_name>Martin Mates</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Všeobecná fakultní nemocnice v Praze</name>
      <address>
        <city>Praha</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomáš Kovárník</last_name>
      <phone>+420 224 96 2687</phone>
      <email>Tomas.Kovarnik@vfn.cz</email>
    </contact>
    <investigator>
      <last_name>Tomáš Kovárník</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut klinické a experimentální medicíny (IKEM)</name>
      <address>
        <city>Praha</city>
        <zip>14021</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Želízko</last_name>
      <phone>+420 236 055 113</phone>
      <email>michael.zelizko@ikem.cz</email>
    </contact>
    <investigator>
      <last_name>Michael Želízko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patent foramen ovale</keyword>
  <keyword>Systemic Embolism</keyword>
  <keyword>Cardiac Shunt</keyword>
  <keyword>Right to left shunt</keyword>
  <keyword>Hemodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

